Another injectable glutathione recall: elevated endotoxin, two ER visits — the fourth Texas compounder this summer

One of the wellness world’s favorite IV drips is back in the FDA’s enforcement reports. Greenwich Rx Compounding Pharmacy of Tomball, Texas, voluntarily recalled 10 lots of compounded glutathione (200 mg/mL in 10 mL multidose vials) on October 1, 2026, citing potential elevated endotoxin levels. The products were distributed to people nationwide between June 26 and September 21, 2026 — and the company says two people required emergency-department care.

What was recalled, and why endotoxin matters

The recalled product is compounded injectable glutathione intended for subcutaneous injection — a peptide therapy marketed for combating cellular damage, supporting the immune system, and liver detoxification. The recall reason is potential elevated endotoxin: bacterial toxins that, in injectable products, can cause fever, low blood pressure, inflammatory reactions, anaphylactic shock, or death. The recall is not yet classified in the FDA’s enforcement database but is expected to land as Class I — the agency’s most serious category, meaning reasonable probability of serious harm or death.

The two ER visits — and an important detail

In its press release, Greenwich Rx said it received two reports of people requiring emergency care after receiving a glutathione product intravenously — that was not formulated for IV use. The recalled vials were intended for subcutaneous injection. The distinction matters: a product’s sterility and endotoxin standards depend on its route, and using a subcutaneous formulation intravenously is a separate, additional risk. Anyone holding vials from the affected lots should stop using them and follow the company’s disposal instructions; the company is notifying customers by mail.

A pattern, not an isolated event

This is the fourth Texas compounding pharmacy to recall glutathione products this summer: Optimal Balance Pharmacy of Houston in July, Victory Medical Center Pharmacy of Austin in August, and Centric Compounding of Houston in September — which we covered when the CDC counted 25+ illnesses. The FDA released compounding-supplier guidance in February 2026 advising compounders to verify that ingredient suppliers test materials and label them properly. The recurring theme across these recalls is manufacturing quality, not the molecule: nothing in this recall says anything about whether glutathione infusions help mitochondria — it says the people making them keep failing basic sterility standards.

Where the evidence stands

• Established: The recall facts — company, lots, dates, endotoxin reason, two ED reports — come from the company press release and the FDA enforcement report; elevated endotoxin in injectables is a known serious hazard.
• Absent: Anything this recall says about glutathione’s efficacy for mitochondrial health — it is a manufacturing-quality failure, not an efficacy finding.